Review of GLP‐1 trials finds low incidence of suicide risk
A systematic review and meta‐analysis comprising 27 trials comparing glucagon‐like peptide 1 (GLP‐1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self‐harm was very low in both the GLP‐1 and placebo groups. Results of the review were published online March 19, 2025, in JAMA Psychiatry .
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1002/pu.31321
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00